Figure 2.
Forest Plot of OS for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment. CI, confidence interval; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not estimable; OS, overall survival; S, sunitinib.